CompletedNCT03206255
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
Studying Vulvar intraepithelial neoplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jun Zhang
- Principal Investigator
- Ting Wu, Ph. D., D.OXiamen University
- Intervention
- 3 doses of HPV 16/18 bivalent vaccine(procedure)
- Enrollment
- 940 target
- Eligibility
- 10-28 years · FEMALE
- Timeline
- 2017 – 2018
Study locations (1)
- Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing, Jiangsu, China
Collaborators
Xiamen Innovax Biotech Co., Ltd · Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03206255 on ClinicalTrials.gov